Phenome-wide association study of *TTR* and *RBP4* genes in 361,194 individuals reveals novel insights in the genetics of hereditary and senile systemic amyloidoses

Antonella De Lillo¹, MSc, Flavio De Angelis¹, PhD, Marco Di Girolamo², MD, Marco Luigetti³, MD, Sabrina Frusconi⁴, BSc, Dario Manfellotto², MD, Maria Fuciarelli¹, PhD, Renato Polimanti^{5,6*} PhD

¹Department of Biology, University of Rome Tor Vergata, Rome, Italy

²Clinical Pathophysiology Center, Fatebenefratelli Foundation – ‘San Giovanni Calibita’ Fatebenefratelli Hospital, Rome, Italy

³Fondazione Policlinico Universitario A. Gemelli IRCCS. UOC Neurologia. Università Cattolica del Sacro Cuore, Rome, Italy

⁴Genetic Diagnostics Unit, Laboratory Department, Careggi University Hospital, Florence, Italy

⁵Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA

⁶VA CT Healthcare Center, West Haven, CT, USA

*Corresponding author:

Dr. Renato Polimanti

Department of Psychiatry, Yale University School of Medicine and VA CT Healthcare Center, VA CT 116A2, 950 Campbell Avenue, West Haven,

CT 06516, USA. Tel: +1 203 932 5711 x5745; Fax: +1 203 937-3897; E-mail:

renato.polimanti@yale.edu

ABSTRACT

Transthyretin (TTR) gene has a causal role in a hereditary form of amyloidosis (ATTRm) and is potentially involved in the risk of senile systemic amyloidosis (SSA). To understand the genetics of ATTRm and SSA, we conducted a phenome-wide association study of *TTR* gene in 361,194 participants of European descent testing coding and non-coding variants. Among the 382 clinically-relevant phenotypes tested, *TTR* non-coding variants were associated with 26 phenotypic traits after multiple testing correction. These included signs related to both ATTRm and SSA such as chronic ischaemic heart disease (rs140226130, $p=2.00 \times 10^{-6}$), heart failure (rs73956431, $p=2.74 \times 10^{-6}$), atrial fibrillation (rs10163755, $p=4.63 \times 10^{-6}$), dysphagia (rs2949506, $p=3.95 \times 10^{-6}$), intestine diseases (rs970866, $p=7.14 \times 10^{-6}$) and anxiety (rs554521234, $p=8.85 \times 10^{-6}$). Consistent results were observed for *TTR* disease-causing mutation Val122Ile (rs76992529) with respect to carpal tunnel syndrome ($p=6.41 \times 10^{-6}$) and mononeuropathies of upper limbs ($p=1.22 \times 10^{-5}$). Sex differences were also observed in line with ATTRm and SSA epidemiology. Additionally, we explored possible modifier genes related to TTR function, observing convergent associations of *RBP4* variants with the clinical phenotypes associated with *TTR* locus. In conclusion, we provide novel insights regarding the molecular basis of ATTRm and SSA based on large-scale cohort, expanding our understanding of the phenotypic spectrum associated with *TTR* gene variation.

Keywords: Transthyretin, genetic variation, amyloidosis, PheWAS, Retinol Binding Protein

4.

INTRODUCTION

Transthyretin (TTR) misfolding and the consequent amyloid formation and deposition lead to two forms of amyloidosis: a hereditary (or mutant) form (ATTRm) caused by more than 100 *TTR* gene coding mutations [1], and a senile systemic form (SSA) that is due to the misfolding of wild type protein (i.e., no *TTR* coding mutation present in the individuals [2].

ATTRm is a life-threatening disorder that affects several tissues (e.g. brain, autonomic and peripheral nerves, heart, and gastrointestinal (GI) tract) and is characterized by an extreme heterogeneity in the genotype-phenotype correlation, including the age of onset, the penetrance, and the clinical display [3-6]. Despite *TTR* coding mutations are the cause of the disease, the clinical variability of the ATTRm is likely due to several other factors [7-11].

Differently from ATTRm, patients affected by SSA do not present a coding mutation in *TTR* gene and the main symptoms include cardiac failure and carpal tunnel syndrome [12-16]. *TTR* non-coding variation via its regulatory function seems to have a role in the phenotypic heterogeneity of ATTRm and to play a role in the pathogenesis of SSA [11,17-19].

Furthermore, variation in other genes encoding for protein products that interact with TTR tetramer seems to modulate the pathogenetic processes involved in the TTR fibrils formation and, consequently, in the course of the disease [20-22]. Genome-wide datasets generated from cohorts including hundred thousand participants can be leveraged to disentangle complex genotype-phenotype associations. In particular, genome-wide association studies (PheWAS) can permit us to detect novel associations with respect to known risk loci with respect to a wide range of phenotypes [23-25]. In the present study, we explored the phenotypic spectrum associated with the coding and non-coding variants of *TTR* gene, also investigating potential modifier loci that could modulate TTR amyloidogenic process. To date, the vast majority of the studies that investigated the genetics of ATTRm and SSA have been conducted on cohorts with a limited sample size due to the low disease prevalence

[9,11,19]. ATTRm and SSA signs are poorly recognized and the correct diagnosis in sporadic cases is usually established several years from the onset of the symptoms [26]. This consistently limited the ability to collect large informative cohorts needed to investigate the genetics of ATTRm and SSA. To date, it is possible to investigate cohorts including hundred thousand participants to explore the association of genetic variation with clinically relevant phenotypes. Accordingly, we conducted a PheWAS in 361,194 participants of European descent available from the UK Biobank with respect to 382 clinically relevant traits to investigate genetic variation potentially involved in TTR-related pathogenic processes. The results obtained support that non-coding variants located in *TTR* gene and other disease-modifying loci are associated with phenotypic traits related to ATTRm and SSA. On the basis of the basis of the current findings, we hypothesize that non-coding variation is involved i) in the variability of genotype-phenotype correlation of carriers of *TTR* coding mutations; and ii) in the increased risk of SSA in non-carriers of *TTR* coding mutations.

MATERIALS AND METHODS

Genome-wide datasets

The dataset used for the analysis was derived from the UK Biobank. This is an open access resource available to investigate a wide range of serious and life-threatening illnesses [27]. This project has recruited more than 500,000 people assessed for a wide range of phenotypic information, also including clinically-relevant phenotypes. Complete genome-wide data are available for the whole cohort. These genetic data were used to generate genome-wide association datasets that can be used to explore the genetics of human diseases and traits. These genome-wide datasets used in the present study were generated on the analysis of 361,194 participants of European descent including 194,174 women and 167,020 men. The

association analysis for all phenotypes was conducted using a linear regression model available in Hail (available at <https://github.com/hail-is/hail>) including the first 20 ancestry principal components, sex, age, age², sex×age, and sex×age² as covariates. Details regarding QC criteria, GWAS methods, and the original data are available at https://github.com/Nealelab/UK_Biobank_GWAS/tree/master/imputed-v2-gwas.

Clinically-relevant Phenotypes

Since our goal was to investigate phenotypes related to the pathogenesis of ATTRm and SSA, we focused on clinically-relevant traits available in the UK Biobank. Specifically, we considered ICD-10 (International Classification of Disease, 10th Revision; [28,29]) codes and clinical endpoints derived by the FinnGen project [<https://www.finnngen.fi/en>]. ICD-10 codes are a specific terminology that include diseases, signs, symptoms, and procedure codes maintained by the World Health Organization (WHO), and they typically are used to billing data [28]. The FinnGen project comes from a collaboration among Finnish universities, biobanks, hospital districts, and several international pharmaceutical companies to increase knowledge about the origins of diseases. FinnGen clinical endpoints (available at <https://www.finnngen.fi/en/researchers/clinical-endpoints>) were developed to conduct genome-wide investigations of phenotypic traits assessed across several national health registers. To remove phenotypes not informative due to a lack of statistical power, we investigated phenotypic traits with a number of cases greater than 1000 individuals. The full list of the phenotypes investigated and their corresponding sample size is reported in the Table S1. Additionally, we also conducted sex-stratified analysis to investigate the known differences between sexes in the epidemiology of ATTRm and SSA. A total of 382, 240, and

225 clinically-relevant phenotypes were investigated in the total sample and in the sex-stratified analysis (female- and male-specific analyses, respectively).

Data Analysis

We considered a total of 382 clinically-relevant phenotypes (sex-stratified analysis: 240 for female-specific PheWAS and 225 for male-specific PheWAS) and investigated variability of *TTR* gene considering a 4-Mb region (NC_000018.9: 27,171,000–31,171,500) including the genic locus (NM_000371; 7,257 bp) and the surrounding regions ($\pm \sim 2$ Mb from the transcription start/end sites) (Table 1). We only considered variants with a minor allele frequency (MAF) greater than 1%. As recommended in the original UK Biobank analysis (information available at <http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas>), we considered high-confidence association results generated from variants with at least 25 minor alleles in the smaller group (case or control). A total of 12,719, 12,710, and 12,711 high-confidence *TTR* variants were investigated in the overall-sample and in the sex-stratified analyses (male- and female-specific, respectively). False Discovery Rate (FDR) at 10% was applied as significance threshold for multiple testing correction [30] accounting for the number of variants and the number of traits tested. To estimate the independent association signals within the genomic region tested, PLINK 1.09 [31] was used to perform linkage disequilibrium (LD) clumping considering a 0.1 R^2 cut-off within a 500-kb window.

STRING v.11.0 [32] was used to identify protein interaction with *TTR*, considering experiments, co-expression, co-occurrence, gene fusion, and neighbourhood as active sources and a confidence score higher than 0.9. With respect to proteins identified, we investigated

variants included in coding, non-coding, and surrounding regions of the encoding gene using the same quality control criteria applied in the analysis of *TTR* variants. Additionally, we investigated the functional enrichments association related to the protein-protein interactions identified considering Gene Ontologies [33,34] for biological processes and molecular functions and molecular pathways available in the Reactome Database [35].

RESULTS

The *TTR* PheWAS identified several phenotypic associations surviving FDR multiple testing correction (Figure 1). These include associations identified in the overall analysis and in the sex-stratified analyses (Figure 2, Table S2). In the analysis of the total cohort (Table S3), we observed several clinical signs that may be related to ATTRm and SSA: spinal stenosis (FinnGen: M13_SPINSTENOSIS; rs116937108, $\beta=0.002$, $p=1.21 \times 10^{-7}$), neuromuscular dysfunction of bladder (ICD-10: N31; rs9953311, $\beta=-0.001$, $p=2.30 \times 10^{-6}$; rs575854233, $\beta=-0.001$, $p=5.33 \times 10^{-6}$), and anxiety disorders (FINNGEN: KRA_PSY_ANXIETY; rs554521234, $\beta=0.003$, $p=8.85 \times 10^{-6}$). Additionally, we also observed significant findings not expected to be directly related to TTR amyloidogenic process: Barret's esophagus (FinnGen: K11_BARRET; rs147570462, $\beta=0.003$, $p=1.19 \times 10^{-7}$), abscess of anal and rectal regions (ICD-10: K61; rs72948149, $\beta=0.002$, $p=1.87 \times 10^{-6}$); fissure and fistula of anal and rectal regions (ICD-10: K60; rs72927361, $\beta=-0.003$, $p=1.90 \times 10^{-6}$); complications of other internal prosthetic devices, implants and grafts (ICD-10: T85; rs34444556, $\beta=0.003$, $p=5.5 \times 10^{-6}$), ulcer of esophagus (FinnGen: K11_OESULC; rs74481699, $\beta=0.004$, $p=6.43 \times 10^{-6}$), adjustment and management of implanted device (ICD-10: Z45; rs117672477, $\beta=0.002$, $p=6.51 \times 10^{-6}$); primary lymphoid and hematopoietic malignant neoplasms (FinnGen: C3_PRIMARY_LYMPHOID_HEMATOPOIETIC; rs17718949,

beta=0.01, $p=6.57 \times 10^{-6}$). Among the 240 clinically-relevant phenotypes tested in the female-specific analysis ($N = 194,174$), we identified 8 LD-independent variants associated with specific pathological conditions (Table S4): chronic ischaemic heart disease (ICD-10: I25; rs140226130, beta=0.003, $p=2.00 \times 10^{-6}$), dysphagia (ICD-10: R13; rs2949506, beta=0.002, $p=3.95 \times 10^{-6}$), other disorders of urinary system (ICD-10: N39; rs71173870, beta=0.003, $p=9.81 \times 10^{-6}$), other specified/unspecified soft tissue disorders (ICD-10: M13_SOFTTISSUENAS; rs558461933, beta=0.007, $p=9.92 \times 10^{-6}$), other cataract (ICD-10: H26; rs12966815, beta=0.003, $p=1.10 \times 10^{-5}$), retinal detachments and breaks (ICD-10: H33; rs117637258, beta=0.003, $p=1.12 \times 10^{-5}$), other abnormal products of conception (ICD-10: O02; rs139327590, beta=0.004, $p=1.16 \times 10^{-5}$), and shoulder lesions (ICD-10: M75; rs77728273, beta=-0.004, $p=1.21 \times 10^{-5}$). Several of these clinical manifestations (e.g., I25~Chronic ischaemic heart disease, R13~Dysphagia, N39~Other disorders of urinary system, H26~Other cataract and H33~Retinal detachments and breaks) seem to be closely related to the expected symptoms of ATTRm and SSA. The male-specific PheWAS (225 phenotypic traits tested) revealed several significant associations that could be related to cardiac, gastrointestinal, and urinary symptoms of ATTRm and SSA (Table S5): other disorders of bladder (ICD-10: N32; rs138038371, beta=0.009, $p=5.01 \times 10^{-7}$), heart failure (FinnGen: I9_HEARTFAIL; rs73956431, beta=0.005, $p=2.74 \times 10^{-6}$), malignant neoplasm of colon (ICD-10: C18; rs78431500, beta=0.006, $p=2.89 \times 10^{-6}$), Barret's esophagus (ICD-10: K11_BARRET; rs147570462, beta=0.005, $p=3.45 \times 10^{-6}$), atrial fibrillation and flutter (ICD-10: I48; rs10163755, beta=0.003, $p=4.63 \times 10^{-6}$), calculus of kidney and ureter (ICD-10: N20; rs8090264, beta=0.002, $p=5.23 \times 10^{-6}$), complications of procedures not elsewhere classified (ICD-10: T81; rs182526571, beta=0.008, $p=6.57 \times 10^{-6}$), other diseases of intestine (ICD-10: K63; rs970866, beta=-0.005, $p=7.14 \times 10^{-6}$) and fibroblastic disorders (FinnGen: M13_FIBROBLASTIC; rs60487427, beta=-0.004, $p=8.38 \times 10^{-6}$).

Amyloidogenic coding variants in *TTR* gene are the established cause of ATTRm [1,5,6]. The large sample size of the UK Biobank cohort includes carriers of *TTR* amyloidogenic mutations with high-quality genotype information (imputation info score > 0.8; Table S6). However, due to the very low MAF of these coding mutations, the phenotypic associations of these variants should be considered only a “low-confidence” result as described in the methods. Being aware of this limitation, we explored their phenotypic spectrum in the UK Biobank (Table 2). The most relevant results were observed for the *TTR* Val122Ile mutation (rs76992529) in the female participants with respect to two well-known symptoms of the amyloidogenic process: carpal tunnel syndrome (FinnGen: G6_CARPTU; beta=0.307, $p=6.41 \times 10^{-6}$) and mononeuropathies of upper limb (ICD-10: G56; beta=0.306, $p=1.22 \times 10^{-5}$).

To test the presence of modifier genes involved in *TTR*-related pathogenic processes, we investigated potential protein interaction and observed the highest-confidence interaction with respect to RBP4 protein, which is supported by experiments and co-expression interaction sources (STRING interaction score = 0.914). The *TTR*-RBP4 protein interaction is associated with functional enrichments for GO terms, including retinol metabolic process (GO:0042572, FDR $q=6.3 \times 10^{-4}$) and protein heterodimerization activity (GO:0046982, FDR $q=0.02$), and for Reactome molecular pathways, including retinol cycle disease events (HSA-2453864, FDR $q=9.98 \times 10^{-6}$), canonical retinoid cycle in rods (HSA-2453902, FDR $q=1.1 \times 10^{-5}$), and retinoid metabolism and transport (HSA-975634, FDR $q=2.84 \times 10^{-5}$). On the basis of these data, we hypothesize a convergence where variants located in *TTR* and *RBP4* genes are associated with clinically-relevant phenotypes related to ATTRm and SSA pathogenesis. Accordingly, we investigated 13,226, 13,231, and 13,217 high-confidence

variants (overall-sample, female-specific, and male-specific analyses, respectively) located in *RBP4* gene and its surrounding regions (NC_000010.10: 93,353,000 – 97,353,500) with respect to the significant phenotypic traits observed in the *TTR* PheWAS (Table 1). We identified significant associations in the overall cohort and in the sex-stratified analyses (Table S2). In the overall sample, we confirmed some of the *TTR* associations previously observed with respect to *TTR* gene that are related to known clinical signs of ATTRm and SSA (Table S7): heart failure (FinnGen: I9_HEARTFAIL; rs1326222, beta=0.001, $p=5.25 \times 10^{-7}$) and anxiety disorders (FinnGen: KRA_PSY_ANXIETY; rs112059561, beta=0.002, $p=6.44 \times 10^{-6}$). Among the phenotypes that do not seem to be related to *TTR* amyloidogenic processes, Barret's esophagus was also significantly associated with a *RBP4* variant (FinnGen: K11_BARRET; rs12573026, beta=0.001, $p=9.96 \times 10^{-8}$). In the female-specific analysis, we observed significant associations with respect to cardiac symptoms which are one of the leading signs of ATTRm and SSA: atrial fibrillation and flutter (ICD-10: I48; rs4917692, beta=0.002, $p=1.15 \times 10^{-5}$) and heart failure (FinnGen: I9_HEARTFAIL; rs1326222, beta=0.001, $p=1.23 \times 10^{-5}$) (Table S8). Finally, in the male participants, we observed a convergence between *RBP4* and *TTR* findings with respect to two additional phenotypes expected to be related to ATTRm and SSA (FinnGen: M13_SPINSTENOSIS~spinal stenosis, rs112288944, beta=0.005, $p=1.42 \times 10^{-5}$; ICD-10: R13~Dysphagia, rs61886346, beta=0.003, $p=1.66 \times 10^{-5}$). Some conditions that are not expected to be linked to amyloidogenic processes such as Barret's esophagus (FinnGen: K11_BARRET; rs12573026, beta=0.002, $p=1.01 \times 10^{-7}$) and malignant neoplasm of colon (ICD-10: C18; rs142083973, beta=0.005, $p=3.40 \times 10^{-6}$) were also associated with both *RBP4* and *TTR* gene variants in the male sample (Table S9). Table S10 summarizes all significant associations, providing the allele frequencies of *TTR* and *RBP4* variants identified.

DISCUSSION

TTR misfolding and the following amyloid formation and deposition are the cause of ATTRm and SSA due to *TTR* coding variants and the misfolding of the wild type protein, respectively [1,2]. With respect to ATTRm, several studies investigated the role of *TTR* coding and non-coding variation to dissect the molecular machineries at the basis of its complex phenotype-genotype correlation [8-11, 17,18, 19]. Differently, limited information is available regarding the genetic basis of SSA [19]. PheWAS design is a powerful tool to broaden the knowledge about the phenotypic spectrum associated with disease-causing genetic variations [23-25] and its performance is enhanced by the availability of genomic data of large cohorts. Accordingly, we conducted a phenome-wide investigation of *TTR* coding and non-coding variants in more than 300,000 participants of European descent, also evaluating the *RBP4* gene as a possible modifier of *TTR* pathogenetic mechanisms.

Our results pointed out novel associations of *TTR* non-coding variants with phenotypic conditions potentially related to ATTRm and SSA pathogenesis. In the sex stratified analysis, we observed strong evidence of the effect of *TTR* non-coding variations on cardiac involvement (ICD-10: I25~Chronic ischaemic heart disease; I48~Atrial fibrillation and flutter; FinnGen: I9_HEARTFAIL~Heart failure, strict), one of the leading clinical signs of ATTRm and SSA. With respect to SSA, heart is the most affected organ in elderly patients, and, the main manifestations are cardiomyopathy (resulting in increase of biventricular wall thickness and ventricular stiffness) and atrial fibrillation [26,36]. The symptoms associated with ATTRm include a restrictive amyloid cardiomyopathy along with a combination of

several other signs, including gait, gastrointestinal, neurological, urinary/renal, and ocular involvement frequently reported among the affected carriers [1,6,26,36].

GI symptoms were identified in our phenome-wide investigation (ICD-10: R13~Dysphagia and K63~Other diseases of intestine). The occurrence of GI manifestations has been reported in both ATTRm and SSA and these include nausea, vomiting, constipation, faecal incontinence, and weight loss [26,37,38]. Although GI involvement is reported in SSA patients, these symptoms are less common than the ones reported in ATTRm [38], where GI manifestations are more frequent in early-onset patients [38].

Significant associations of *TTR* variants with respect to bladder, urinary tract and kidney were identified in the overall sample and in the sex-stratified analyses (ICD-10: N31~Neuromuscular dysfunction of bladder, not elsewhere classified; N39~Other disorders of urinary system; N32~Other disorders of bladder; N20~Calculus of kidney and ureter). It is well known the evolution of neurogenic bladder in ATTRm that is linked to autonomic nerve dysfunction, and, renal involvement due to the amyloid deposition in the glomeruli arterioles and medium vessels [26,39].

The female sample showed that *TTR* non-coding variants are associated with ocular involvement (ICD-10: H26~Other cataract; H33~Retinal detachments and breaks). These findings are consistent with the known ocular manifestations described in ATTRm, which, in agreement with our sex-stratified result, occur more frequently in women [40]. The ocular symptoms reported in ATTRm patients include vitreous opacities, retinal vein occlusion and direct optic nerve infiltration[40].

Remarkably, a significant genetic association between *TTR* gene and anxiety disorders (FinnGen: KRA_PSY_ANXIETY) was observed. There is a growing literature regarding the effect of rare life-threatening diseases on the mental health of the patients and their families. With respect to ATTRm, several studies reported considerable psychological consequences in carriers of *TTR* mutations after the onset of the symptoms and the diagnosis of the disease [41,42]. These behavioural changes seem to be related to the stressful scenarios related to amyloidosis diagnostic path, including the pre-symptomatic genetic testing confirming the presence of an amyloidogenic mutation in family members and the time (usually years) intervening between the onset of the symptoms and the diagnosis of the diseases in novel ATTRm cases.

Spinal stenosis (FinnGen: M13_SPINSTENOSIS) was another phenotype identified in our *TTR* Phewas. This symptom has been reported in both ATTRm and SSA patients [26,36], and it usually co-occurs with other known signs of *TTR* amyloidogenic process such as carpal tunnel syndrome and neuropathies [43]. These phenotypic traits were identified as associated to *TTR* Val122Ile mutation (Table 2). This is also consistent with phenotypic presentation of Val122Ile carriers affected by ATTRm where the carpal tunnel syndrome represents an early sign of the disease whereas upper limb involvement is a clinical manifestation observed in a later stage [26]. Although our findings are related to carriers of European descent and Val122Ile mutation is mainly identified in individuals of African descent, a similar clinical phenotype has been reported in Val122Ile carriers of both ancestry groups [44].

Our findings support a phenotypic convergence between *TTR* and *RBP4* genetic associations, also including traits expected to be associated with ATTRm and SSA clinical spectrum (i.e., heart failure and atrial fibrillation). This evidence supports the putative role of *RBP4* as modifier gene with respect to TTR amyloidogenic process. RBP4 interacts with TTR via formation of TTR-RBP4 protein complex that stabilizes the TTR tetramer, inhibiting monomer dissociation and fibril formation [3]. In carriers of *TTR* amyloidogenic mutations, there is an increase of the TTR tetramer dissociation with a consequent decrease of the TTR-RBP4 complex and an increase of the RBP4 urinary excretion [3,45]. Accordingly, *RBP4* genetic variation could affect the functionality of the TTR-RBP4 complex, contributing to the complex phenotype-genotype correlation in carriers of *TTR* amyloidogenic mutations and increasing the risk of SSA in non-carriers.

Both *TTR* and *RBP4* association analyses identified traits that are not expected to be related to the pathological consequences of the amyloidogenic process. However, they may be related to the inter-individual variability of the main physiological function of these two genes: the transport of retinol (vitamin A) [46]. Altered homeostasis of vitamin is associated with several disorders [47] and some of them could be associated with the effect of *TTR* and *RBP4* variants on retinol metabolism, explaining some of the phenotypic traits identified in the present study.

In conclusion, the present study provides novel insights about *TTR* gene variation, confirming its role in phenotypic variability observed in ATTRm patients and supporting its potential involvement in the predisposition to SSA. These data support the relevance of large biobanks to investigate complex genotype-phenotype associations. Additionally, the insights provided

support the necessity of further investigations of *TTR* non-coding variation together with putative modifier loci to develop tools able to anticipate the course of the disease in order to improve the diagnosis and management of patients affected by ATTRm and SSA.

LIST OF ABBREVIATIONS

ATTRm, transthyretin-related hereditary (or mutant) form of amyloidosis; FDR, false discovery rate; GI, gastrointestinal; ICD-10, International Classification of Diseases 10th Revision; MAF, minor allele frequency; PheWAS, phenome wide association study; RBP4, retinol-binding protein 4; SSA, senile systemic amyloidosis; TTR, transthyretin; WHO, World Health Organization.

DECLARATIONS

Ethics approval and consent to participate

Owing to the use of previously collected, de-identified, aggregated data, this study did not require institutional review board approval.

Availability of data and materials

All data generated during this study are included in this published article and its Supplemental information files.

Competing Interests

Drs. Fuciarelli and Polimanti are both receiving research grants from Pfizer Inc. to conduct epigenetic studies of TTR amyloidosis. The other authors reported no biomedical financial interests or potential conflicts of interest.

Funding

This work was partially supported by the PhD Program of the University of Rome Tor Vergata (ADL) and the Yale University School of Medicine (RP).

Author contributions

ADL and RP were involved in study design. ADL and RP carried out statistical analysis. All authors were involved in the interpretation of the results. ADL and RP wrote the first draft of the manuscript and all authors contributed to the final version of the manuscript.

Acknowledgments

We thank the participants and investigators of the UK Biobank and the Neale lab for generating the genome-wide data used in the present study.

REFERENCES

1. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. *Lancet Neurol*. 2011;10(12):1086-1097.
2. Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. *Proc. Natl. Acad. Sci. U. S. A.* 1990;87(7):2843-2845.
3. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? *Curr Med Chem*. 2012;19(15):2324-2342.
4. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. *Amyloid*. 2008;15(3):181-186.
5. Conceicao I. Clinical features of TTR-FAP in Portugal. *Amyloid*. 2012;19 Suppl 1:71-72.
6. Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. *Curr Opin Neurol*. 2016;29 Suppl 1:S3-S13.
7. Alves-Ferreira M, Coelho T, Santos D, et al. A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal. *Mol Neurobiol*. 2018;55(5):3676-3683.

8. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis. *Amyloid*. 2014;21(3):154-162.
9. Iorio A, De Angelis F, Di Girolamo M, et al. Most recent common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-phenotype correlation. *Amyloid*. 2015;22(2):73-78.
10. Iorio A, De Angelis F, Di Girolamo M, et al. Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis. *BMC Genomics*. 2017;18(1):254.
11. Iorio A, De Lillo A, De Angelis F, et al. Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. *Eur J Hum Genet*. 2017;25(9):1055-1060.
12. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. *Semin Hematol*. 1995;32(1):45-59.
13. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation*. 2005;111(2):186-193.
14. Pitkanen P, Westermark P, Cornwell GG, 3rd. Senile systemic amyloidosis. *Am J Pathol*. 1984;117(3):391-399.
15. Connors LH, Doros G, Sam F, Badiie A, Seldin DC, Skinner M. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. *Amyloid*. 2011;18 Suppl 1:157-159.
16. Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. *Amyloid*. 2016;23(1):58-63.
17. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes. *Amyloid*. 2013;20(4):256-262.
18. Polimanti R, Nunez YZ, Gelernter J. Increased Risk of Multiple Outpatient Surgeries in African-American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. *J Clin Med*. 2019;8(2).
19. Sikora JL, Logue MW, Chan GG, et al. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). *Hum Genet*. 2015;134(1):111-121.
20. Soares ML, Coelho T, Sousa A, et al. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. *Hum Mol Genet*. 2005;14(4):543-553.
21. Santos D, Coelho T, Alves-Ferreira M, et al. Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). *Eur J Hum Genet*. 2016;24(5):756-760.
22. White JT, Kelly JW. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. *Proc. Natl. Acad. Sci. U. S. A*. 2001;98(23):13019-13024.
23. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nat Biotechnol*. 2013;31(12):1102-1110.
24. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. *Nat Rev Genet*. 2016;17(3):129-145.
25. Polimanti R, Kranzler HR, Gelernter J. Phenome-Wide Association Study for Alcohol and Nicotine Risk Alleles in 26394 Women. *Neuropsychopharmacology*. 2016;41(11):2688-2696.

26. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8:31.
27. Allen NE, Sudlow C, Peakman T, Collins R, Biobank UK. UK biobank data: come and get it. *Sci Transl Med*. 2014;6(224):224ed224.
28. Denny JC. Chapter 13: Mining electronic health records in the genomics era. *PLoS Comput. Biol*. 2012;8(12):e1002823.
29. Wei WQ, Denny JC. Extracting research-quality phenotypes from electronic health records to support precision medicine. *Genome Med*. 2015;7(1):41.
30. Benjamini Y, Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995;57:289-300.
31. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7.
32. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res*. 2019;47(D1):D607-D613.
33. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*. 2000;25(1):25-29.
34. The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res*. 2019;47(D1):D330-D338.
35. Fabregat A, Jupe S, Matthews L, et al. The Reactome Pathway Knowledgebase. *Nucleic Acids Res*. 2018;46(D1):D649-D655.
36. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. *Trends Cardiovasc Med*. 2018;28(1):10-21.
37. Collins M, Pellat A, Antoni G, et al. Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy. *PLoS One*. 2018;13(8):e0201869.
38. Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. *Orphanet J Rare Dis*. 2014;9:61.
39. Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. *Clin J Am Soc Nephrol*. 2012;7(8):1337-1346.
40. Reynolds MM, Veverka KK, Gertz MA, et al. Ocular Manifestations of Familial Transthyretin Amyloidosis. *Am J Ophthalmol*. 2017;183:156-162.
41. Graceffa A, Russo M, Vita GL, et al. Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. *Neuromuscul Disord*. 2009;19(1):44-48.
42. Lopes A, Sousa A, Fonseca I, et al. Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study. *J Community Genet*. 2018;9(1):93-99.
43. Carr AS, Shah S, Choi D, et al. Spinal Stenosis in Familial Transthyretin Amyloidosis. *J Neuromuscul Dis*. 2019;6(2):267-270.
44. Cappelli F, Frusconi S, Bergesio F, et al. The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience. *J Cardiovasc Med (Hagerstown)*. 2016;17(2):122-125.
45. Arvanitis M, Koch CM, Chan GG, et al. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. *JAMA Cardiol*. 2017;2(3):305-313.
46. Noy N. Vitamin A in regulation of insulin responsiveness: mini review. *Proc Nutr Soc*. 2016;75(2):212-215.

47. Mason J, Greiner T, Shrimpton R, Sanders D, Yukich J. Vitamin A policies need rethinking. *Int J Epidemiol.* 2015;44(1):283-292.

Legends:

Figure 1: Manhattan Plot of *TTR* PheWAS in the total sample and in sex-stratified analyses across the different phenotypic categories tested.

Figure 2: Significant associations of *TTR* non-coding variants with clinically-relevant phenotypes in the total sample and in the sex-stratified analyses. The full details of the associations are reported in Table S2.

Table 1: Details regarding the clinically-relevant traits and the genomic regions tested in the overall cohort and in the sex-stratified analyses.

Table 2: Significant associations identified with respect to *TTR* coding mutations. Information about beta value, se, p-value and FDR q-value are reported. Bold text: *TTR* protein substitution. Underline text: *TTR* precursor substitution. Information about allele frequency and minor allele frequency are reported in Table S9.

Table S1: Clinically-relevant phenotypic traits investigated.

Table S2: Clinically-relevant phenotypes identified as significant in the *TTR* PheWAS. We report the Z scores observed in the overall analysis and in the sex-stratified analysis for both *TTR* and *RBP4*. Z scores surviving multiple testing correction are highlighted in bold. NA indicates associations not tested due the quality control applied. NS indicates phenotypes not significantly associated with *RBP4* variants.

Table S3: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits in the overall-sample analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S4: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits related in the female-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S5: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits related in the male-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S6: *TTR* coding mutations in the UK Biobank sample investigated. Rsid, localization, imputation score, allelic frequency (AF), precursor and/or protein substitution, consequences of variants are reported.

Table S7: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the overall-sample analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S8: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the female-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S9: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the male-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Table S10: Allele frequencies of *TTR* and *RBP4* significant variants identified. Ref = reference allele on the forward strand; alt = alternate allele (not necessarily minor allele); AF = allele frequency; MAF = minor allele frequency in the n_complete_samples defined for associated phenotype.

Manhattan Plot of *TTR* PheWAS in the total sample and in sex-stratified analyses across the different phenotypic categories tested.

Figure 2: Significant associations of *TTR* non-coding variants with clinically-relevant phenotypes in the total sample and in the sex-stratified analyses. The full details of the associations are reported in Table S2.

Table 1: Details regarding the clinically-relevant traits and the genomic regions tested in the overall cohort and in the sex-stratified analyses.

Gene	Localization	Sex	Phenotype N	Case Median N (Min – Max)	Control Median N (Min-Max)
<i>TTR</i>	NC_000018.9: 27,171,000 – 31,171,500	BOTH SEXES	382	2,534 (1011 – 208,009)	358,660 (79,185 – 360,183)
		FEMALE	240	2,364 (1,008 – 153,946)	191,810 (40,228 – 193,166)
		MALE	225	2,533 (1,004 – 128,063)	164,487 (39,957 – 166,016)
<i>RBP4</i>	NC_000010.10: 93,353,000 – 97,353,500	BOTH SEXES	32 ^a	2,820 (1,014 – 20,857)	358,374 (340,337 – 360,180)
		FEMALE	32 ^a	1,095 (331 – 7,355)	193,079 (186,819 – 193,843)
		MALE	31 ^a	1,581 (441 – 15,056)	165,439 (151,964 – 166,579)

^asignificant phenotypic traits identified in the *TTR* PheWAS and tested in the *RBP4* analysis.

Table 2: Significant associations identified with respect to *TTR* coding mutations. Information about beta value, se, p-value and FDR q-value are reported. Bold text: TTR protein substitution. Underline text: TTR precursor substitution. Information about allele frequency and minor allele frequency are reported in Table S9.

PHENOTYPIC TRAIT		RSID	SUBSTITUTION	BETA	SE	P-VALUE	FDR
Both sexes	FinnGen: XVII_MALFORMAT_ABNORMAL~Congenital malformations, deformations and chromosomal abnormalities	rs138657343	<u>Arg5His</u>	0.0264	0.00550	1.64×10^{-6}	0.029
Female	ICD10: R87~Abnormal findings in specimens from female genital organs	rs138657343	<u>Arg5His</u>	0.0379	0.00724	1.65×10^{-7}	0.004
	FinnGen: XVII_MALFORMAT_ABNORMAL~Congenital malformations, deformations and chromosomal abnormalities			0.0368	0.00756	1.12×10^{-6}	0.019
	ICD10: N94~Pain and other conditions associated with female genital organs and menstrual cycle	rs76992529	Val122Ile	0.158	0.0334	2.31×10^{-6}	0.032
	FinnGen: G6_CARPTU~Carpal tunnel syndrome			0.307	0.0681	6.41×10^{-6}	0.063
	ICD10: G56~Mononeuropathies of upper limb			0.306	0.0699	1.22×10^{-5}	0.079
	FinnGen: K11_HERNIA~Hernia	rs121918074	His90Asn	0.210	0.0485	1.53×10^{-5}	0.090

Table S1: Clinically-relevant phenotypic traits investigated.

Code	Description	Source	N	N cases	N controls
A09	Diagnoses - main ICD10: A09 Diarrhoea and gastro-enteritis of presumed infectious origin	icd10	361194	2161	359033
A41	Diagnoses - main ICD10: A41 Other septicaemia	icd10	361194	1096	360098
AB1_INFECTIONS	Certain infectious and parasitic diseases	finngen	361194	7530	353664
AB1_INTESTINAL_INFECTIONS	Intestinal infectious diseases	finngen	361194	4304	356890
AB1_OTHER_BACTERIAL	Other bacterial diseases	finngen	361194	1962	359232
AB1_OTHER_VIRAL	Other viral diseases	finngen	361194	1180	360014
ASTHMA_CHILD	Childhood asthma (age<16)	finngen	361194	1993	359201
ASTHMA_EOSINOPHIL_SUGG	Suggestive for eosinophilic asthma	finngen	361194	2302	358892
ASTHMA_HOSPITAL1	Asthma, hospital admissions 1	finngen	361194	1986	359208
ASTHMA_MEDICATION_COMORB	Medication related adverse effects	finngen	361194	20094	341100
ASTHMA_PNEUMONIA	Asthma-related pneumonia	finngen	361194	5900	355294
BRONCHITIS	Bronchitis	finngen	361194	4283	356911
C_BREAST_3	Malignant neoplasm of breast	finngen	361194	9721	351473
C_BRONCHUS_LUNG	Malignant neoplasm of bronchus and lung	finngen	361194	1681	359513
C_COLON	Malignant neoplasm of colon	finngen	361194	2437	358757
C_CORPUS_UTERI	Malignant neoplasm of corpus uteri	finngen	361194	1222	359972
C_DIGESTIVE_ORGANS	NA	finngen	361194	5690	355504
C_FEMALE_GENITAL	NA	finngen	361194	2603	358591
C_LYMPHOMA	Lymphomas	finngen	361194	1752	359442
C_MALE_GENITAL	NA	finngen	361194	6795	354399
C_MELANOMA_SKIN	Malignant melanoma of skin	finngen	361194	2534	358660
C_OTHER_SKIN	Other malignant neoplasms of skin	finngen	361194	14402	346792
C_PRIMARY_LYMPHOID_HEMATOPOIETIC	NA	finngen	361194	3030	358164
C_PROSTATE	Malignant neoplasm of prostate	finngen	361194	6321	354873
C_RECTUM	Malignant neoplasm of rectum	finngen	361194	1170	360024
C_RESPIRATORY_INTRATHORACIC	NA	finngen	361194	1944	359250
C_SKIN	NA	finngen	361194	16531	344663
C_STROKE	STROKE	finngen	361194	6146	355048

C_URINARY_TRACT	NA	finngen	361194	1841	359353
C18	Diagnoses - main ICD10: C18 Malignant neoplasm of colon	icd10	361194	2226	358968
C20	Diagnoses - main ICD10: C20 Malignant neoplasm of rectum	icd10	361194	1118	360076
C3_BREAST_3	Malignant neoplasm of breast	finngen	361194	9721	351473
C3_BRONCHUS_LUNG	Malignant neoplasm of bronchus and lung	finngen	361194	1681	359513
C3_COLON	Malignant neoplasm of colon	finngen	361194	2437	358757
C3_CORPUS_UTERI	Malignant neoplasm of corpus uteri	finngen	361194	1222	359972
C3_DIGESTIVE_ORGANS	Malignant neoplasm of digestive organs	finngen	361194	5690	355504
C3_FEMALE_GENITAL	malignant neoplasm of female genital organs	finngen	361194	2603	358591
C3_MALE_GENITAL	malignant neoplasm of male genital organs	finngen	361194	6795	354399
C3_MELANOMA_SKIN	Malignant melanoma of skin	finngen	361194	2534	358660
C3_OTHER_SKIN	Other malignant neoplasms of skin	finngen	361194	14402	346792
C3_PRIMARY_LYMPHOID_HEMATOPOIETIC	Primary_lymphoid and hematopoietic malignant neoplasms	finngen	361194	2710	358484
C3_PROSTATE	Malignant neoplasm of prostate	finngen	361194	6321	354873
C3_RECTUM	Malignant neoplasm of rectum	finngen	361194	1170	360024
C3_RESPIRATORY_INTRATHORACIC	Malignant neoplasm of respiratory system and intrathoracic organs	finngen	361194	1944	359250
C3_SKIN	Malignant neoplasm of skin	finngen	361194	16531	344663
C3_URINARY_TRACT	Malignant neoplasm of urinary organs	finngen	361194	1841	359353
C34	Diagnoses - main ICD10: C34 Malignant neoplasm of bronchus and lung	icd10	361194	1427	359767
C43	Diagnoses - main ICD10: C43 Malignant melanoma of skin	icd10	361194	1672	359522
C44	Diagnoses - main ICD10: C44 Other malignant neoplasms of skin	icd10	361194	9086	352108
C50	Diagnoses - main ICD10: C50 Malignant neoplasm of breast	icd10	361194	8304	352890
C61	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	icd10	361194	4342	356852
C67	Diagnoses - main ICD10: C67 Malignant neoplasm of bladder	icd10	361194	1554	359640
C78	Diagnoses - main ICD10: C78 Secondary malignant neoplasm of respiratory and digestive organs	icd10	361194	1378	359816

C79	Diagnoses - main ICD10: C79 Secondary malignant neoplasm of other sites	icd10	361194	1099	360095
CARDIAC_ARRHYTM	Cardiac arrhythmias, COPD co-morbidities	finngen	361194	8801	352393
COLITNONINFNAS	Noninfectious colitis NAS	finngen	361194	8945	352249
COPD_EARLYANDLATER	COPD, early/late onset	finngen	361194	1897	359297
COPD_EXCL	COPD differential diagnosis	finngen	361194	26710	334484
COX_ARTHROSIS	Coxarthrosis [arthrosis of hip](FG)	finngen	361194	9410	351784
D05	Diagnoses - main ICD10: D05 Carcinoma in situ of breast	icd10	361194	1454	359740
D12	Diagnoses - main ICD10: D12 Benign neoplasm of colon, rectum, anus and anal canal	icd10	361194	8877	352317
D17	Diagnoses - main ICD10: D17 Benign lipomatous neoplasm	icd10	361194	4314	356880
D22	Diagnoses - main ICD10: D22 Melanocytic naevi	icd10	361194	3501	357693
D23	Diagnoses - main ICD10: D23 Other benign neoplasms of skin	icd10	361194	3085	358109
D24	Diagnoses - main ICD10: D24 Benign neoplasm of breast	icd10	361194	1089	360105
D25	Diagnoses - main ICD10: D25 Leiomyoma of uterus	icd10	361194	5507	355687
D3_ANAEMIA_IRONDEF	Iron deficiency anaemia	finngen	361194	3786	357408
D3_ANAEMIANAS	Other and unspecified anaemias	finngen	361194	4291	356903
D3_OTHERANAEMIA	Other anaemias	finngen	361194	4294	356900
D50	Diagnoses - main ICD10: D50 Iron deficiency anaemia	icd10	361194	3222	357972
D64	Diagnoses - main ICD10: D64 Other anaemias	icd10	361194	3702	357492
E04	Diagnoses - main ICD10: E04 Other non-toxic goitre	icd10	361194	1052	360142
F5_DEPRESSIO	Depression	finngen	361194	1145	360049
F5_MOOD	Mood [affective] disorders	finngen	361194	1546	359648
FIBRO_COMORB	Fibromyalgia related co-morbidities	finngen	361194	2305	358889
G43	Diagnoses - main ICD10: G43 Migraine	icd10	361194	1072	360122
G45	Diagnoses - main ICD10: G45 Transient cerebral ischaemic attacks and related syndromes	icd10	361194	1744	359450
G47	Diagnoses - main ICD10: G47 Sleep disorders	icd10	361194	2723	358471
G56	Diagnoses - main ICD10: G56 Mononeuropathies of upper limb	icd10	361194	8130	353064

G57	Diagnoses - main ICD10: G57 Mononeuropathies of lower limb	icd10	361194	1111	360083
G6_CARPTU	Carpal tunnel syndrome	finngen	361194	7973	353221
G6_EPIPAROX	Episodal and paroxysmal disorders	finngen	361194	5418	355776
G6_NERPLEX	Nerve, nerve root and plexus disorders	finngen	361194	10898	350296
G6_SLEEPAPNO	Sleep apnoea	finngen	361194	2249	358945
H00	Diagnoses - main ICD10: H00 Hordeolum and chalazion	icd10	361194	1467	359727
H02	Diagnoses - main ICD10: H02 Other disorders of eyelid	icd10	361194	4294	356900
H04	Diagnoses - main ICD10: H04 Disorders of lachrymal system	icd10	361194	1476	359718
H25	Diagnoses - main ICD10: H25 Senile cataract	icd10	361194	6332	354862
H26	Diagnoses - main ICD10: H26 Other cataract	icd10	361194	11306	349888
H33	Diagnoses - main ICD10: H33 Retinal detachments and breaks	icd10	361194	2671	358523
H35	Diagnoses - main ICD10: H35 Other retinal disorders	icd10	361194	1551	359643
H40	Diagnoses - main ICD10: H40 Glaucoma	icd10	361194	1715	359479
H7_CHALAZION	Chalazion	finngen	361194	1418	359776
H7_EYELIDDIS	Other disorders of eyelid	finngen	361194	4529	356665
H7_EYELIDNAS	Other specified and unspecified disorders of eyelid	finngen	361194	2186	359008
H7_LACRIMALSYSTEM	Disorders of lacrimal system	finngen	361194	1555	359639
H7_LENS	Disorders of lens	finngen	361194	17076	344118
H7_MACULADEGEN	Degeneration of macula and posterior pole	finngen	361194	1013	360181
H7_RETINALDETACH	Retinal detachments and breaks	finngen	361194	3043	358151
H7_RETINALDETACHBREAK	Retinal detachment with retinal break	finngen	361194	1198	359996
H7_RETINALDISOTH	Other retinal disorders	finngen	361194	1692	359502
HEARTFAIL	Heart failure	finngen	361194	1405	359789
I_INFECT_PARASIT	Certain infectious and parasitic diseases	finngen	361194	9297	351897
I20	Diagnoses - main ICD10: I20 Angina pectoris	icd10	361194	6246	354948
I21	Diagnoses - main ICD10: I21 Acute myocardial infarction	icd10	361194	5948	355246
I25	Diagnoses - main ICD10: I25 Chronic ischaemic heart disease	icd10	361194	12769	348425
I26	Diagnoses - main ICD10: I26 Pulmonary	icd10	361194	2118	359076

	embolism				
I47	Diagnoses - main ICD10: I47 Paroxysmal tachycardia	icd10	361194	1685	359509
I48	Diagnoses - main ICD10: I48 Atrial fibrillation and flutter	icd10	361194	6356	354838
I50	Diagnoses - main ICD10: I50 Heart failure	icd10	361194	1088	360106
I63	Diagnoses - main ICD10: I63 Cerebral infarction	icd10	361194	2353	358841
I80	Diagnoses - main ICD10: I80 Phlebitis and thrombophlebitis	icd10	361194	2289	358905
I83	Diagnoses - main ICD10: I83 Varicose veins of lower extremities	icd10	361194	8763	352431
I84	Diagnoses - main ICD10: I84 Haemorrhoids	icd10	361194	12102	349092
I9_ARTOTH	Other diseases of arteries and capillaries	finngen	361194	1083	360111
I9_CHD	Major coronary heart disease event	finngen	361194	10157	351037
I9_CHD_NOREV	Major coronary heart disease event excluding revascularizations	finngen	361194	10157	351037
I9_CONDUCTIO	Conduction disorders	finngen	361194	1055	360139
I9_CORATHER	Coronary atherosclerosis	finngen	361194	14334	346860
I9_DISVEINLYMPH	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	finngen	361194	11867	349327
I9_DVTANDPULM	DVT of lower extremities and pulmonary embolism	finngen	361194	4319	356875
I9_HEARTFAIL	Heart failure,strict	finngen	361194	1405	359789
I9_HEARTFAIL_NS	Heart failure, not strict	finngen	361194	1405	359789
I9_HYPERTENSION	Hypertensive diseases	finngen	361194	1313	359881
I9_HYPTENS	Hypertension	finngen	361194	1237	359957
I9_IHD	Ischaemic heart disease, wide definition	finngen	361194	20857	340337
I9_INTRACRA	Nontraumatic intracranial haemorrhage	finngen	361194	1253	359941
I9_K_CARDIAC	Death due to cardiac causes	finngen	361194	1597	359597
I9_MI	Myocardial infarction	finngen	361194	7018	354176
I9_MI_STRICT	Myocardial infarction, strict	finngen	361194	7018	354176
I9_NONRHEVALV	Non-rheumatic valve diseases	finngen	361194	1606	359588
I9_PAD	Peripheral artery disease	finngen	361194	1230	359964
I9_PHELETHROMBDVTLOW	DVT of lower extremities	finngen	361194	2116	359078
I9_STR	Stroke, excluding SAH	finngen	361194	3832	357362
I9_STR_EXH	Ischaemic Stroke, excluding all haemorrhages	finngen	361194	3314	357880

I9_STR_SAH	Stroke, including SAH	finngen	361194	4484	356710
I9_UAP	Unstable angina pectoris	finngen	361194	3439	357755
I9_VTE	Venous thromboembolism	finngen	361194	4620	356574
IBD_ENDOMETRIOSIS	Endometriosis, IBD co-morbidity	finngen	361194	1516	359678
ICDMAIN_ANY_ENTRY	Any ICDMAIN event in hilmo or causes of death	finngen	361194	282009	79185
II_NEOPLASM	Neoplasms	finngen	361194	70178	291016
III_BLOOD_IMMUN	Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	finngen	361194	10095	351099
ILD_DIFF_DG	ILD differential diagnosis	finngen	361194	26710	334484
IV_ENDOCRIN_NUTRIT	Endocrine, nutritional and metabolic diseases	finngen	361194	7218	353976
IX_CIRCULATORY	Diseases of the circulatory system	finngen	361194	60504	300690
J10_ASTHMA	Asthma	finngen	361194	1993	359201
J10_ASTHMA_MAIN	Asthma	finngen	361194	1993	359201
J18	Diagnoses - main ICD10: J18 Pneumonia, organism unspecified	icd10	361194	4630	356564
J22	Diagnoses - main ICD10: J22 Unspecified acute lower respiratory infection	icd10	361194	3140	358054
J32	Diagnoses - main ICD10: J32 Chronic sinusitis	icd10	361194	1179	360015
J33	Diagnoses - main ICD10: J33 Nasal polyp	icd10	361194	2207	358987
J34	Diagnoses - main ICD10: J34 Other disorders of nose and nasal sinuses	icd10	361194	4438	356756
J38	Diagnoses - main ICD10: J38 Diseases of vocal cords and larynx, not elsewhere classified	icd10	361194	1168	360026
J44	Diagnoses - main ICD10: J44 Other chronic obstructive pulmonary disease	icd10	361194	1531	359663
J45	Diagnoses - main ICD10: J45 Asthma	icd10	361194	1693	359501
J90	Diagnoses - main ICD10: J90 Pleural effusion, not elsewhere classified	icd10	361194	1033	360161
K01	Diagnoses - main ICD10: K01 Embedded and impacted teeth	icd10	361194	1443	359751
K02	Diagnoses - main ICD10: K02 Dental caries	icd10	361194	2110	359084
K04	Diagnoses - main ICD10: K04 Diseases of pulp and periapical tissues	icd10	361194	1609	359585
K08	Diagnoses - main ICD10: K08 Other disorders of teeth and supporting structures	icd10	361194	1838	359356
K11_APPENDIX	Diseases of appendix	finngen	361194	2953	358241

K11_BARRET	Barret esophagus	finngen	361194	1791	359403
K11_CHRONGASTR	Chronic gastritis	finngen	361194	1790	359404
K11_GALLBILPANC	Disorders of gallbladder, biliary tract and pancreas	finngen	361194	13922	347272
K11_GASTRODUOULC	Gastroduodenal ulcer	finngen	361194	3467	357727
K11_GIBLEEDING	GI-bleeding	finngen	361194	5235	355959
K11_HERNIA	Hernia	finngen	361194	26197	334997
K11_ILEUS	Paralytic ileus and intestinal obstruction	finngen	361194	2102	359092
K11_LIVER	Diseases of liver	finngen	361194	1663	359531
K11_OESULC	Ulcer of esophagus	finngen	361194	3098	358096
K11_OTHDIG	Other diseases of the digestive system	finngen	361194	7063	354131
K11_OTHDISOES	Other diseases of esophagus	finngen	361194	1185	360009
K11_OTHGASTR	Other gastritis (incl. Duodenitis)	finngen	361194	10518	350676
K11_OTHILEUS	Other or unspecified ileus, impaction or obstruction	finngen	361194	1350	359844
K13	Diagnoses - main ICD10: K13 Other diseases of lip and oral mucosa	icd10	361194	2157	359037
K20	Diagnoses - main ICD10: K20 Oesophagitis	icd10	361194	4799	356395
K21	Diagnoses - main ICD10: K21 Gastro-oesophageal reflux disease	icd10	361194	10743	350451
K22	Diagnoses - main ICD10: K22 Other diseases of esophagus	icd10	361194	5494	355700
K25	Diagnoses - main ICD10: K25 Gastric ulcer	icd10	361194	1834	359360
K26	Diagnoses - main ICD10: K26 Duodenal ulcer	icd10	361194	1291	359903
K29	Diagnoses - main ICD10: K29 Gastritis and duodenitis	icd10	361194	12678	348516
K30	Diagnoses - main ICD10: K30 Dyspepsia	icd10	361194	7586	353608
K31	Diagnoses - main ICD10: K31 Other diseases of stomach and duodenum	icd10	361194	2374	358820
K35	Diagnoses - main ICD10: K35 Acute appendicitis	icd10	361194	2404	358790
K40	Diagnoses - main ICD10: K40 Inguinal hernia	icd10	361194	13147	348047
K42	Diagnoses - main ICD10: K42 Umbilical hernia	icd10	361194	2528	358666
K43	Diagnoses - main ICD10: K43 Ventral hernia	icd10	361194	2249	358945
K44	Diagnoses - main ICD10: K44 Diaphragmatic hernia	icd10	361194	8042	353152
K51	Diagnoses - main ICD10: K51 Ulcerative colitis	icd10	361194	2143	359051

K52	Diagnoses - main ICD10: K52 Other non-infective gastro-enteritis and colitis	icd10	361194	8757	352437
K56	Diagnoses - main ICD10: K56 Paralytic ileus and intestinal obstruction without hernia	icd10	361194	1851	359343
K57	Diagnoses - main ICD10: K57 Diverticular disease of intestine	icd10	361194	12662	348532
K58	Diagnoses - main ICD10: K58 Irritable bowel syndrome	icd10	361194	1121	360073
K59	Diagnoses - main ICD10: K59 Other functional intestinal disorders	icd10	361194	3712	357482
K60	Diagnoses - main ICD10: K60 Fissure and fistula of anal and rectal regions	icd10	361194	2109	359085
K61	Diagnoses - main ICD10: K61 Abscess of anal and rectal regions	icd10	361194	1053	360141
K62	Diagnoses - main ICD10: K62 Other diseases of anus and rectum	icd10	361194	13882	347312
K63	Diagnoses - main ICD10: K63 Other diseases of intestine	icd10	361194	8041	353153
K80	Diagnoses - main ICD10: K80 Cholelithiasis	icd10	361194	10520	350674
K81	Diagnoses - main ICD10: K81 Cholecystitis	icd10	361194	1930	359264
K85	Diagnoses - main ICD10: K85 Acute pancreatitis	icd10	361194	1292	359902
K92	Diagnoses - main ICD10: K92 Other diseases of digestive system	icd10	361194	5019	356175
KNEE_ARTHROSIS	Gonarthrosis [arthrosis of knee](FG)	finngen	361194	11900	349294
KRA_PSY_ANXIETY	Anxiety disorders	finngen	361194	1092	360102
KRA_PSY_ANYMENTAL	Any mental disorder	finngen	361194	4304	356890
KRA_PSY_MOOD	Mood disorders	finngen	361194	1546	359648
L02	Diagnoses - main ICD10: L02 Cutaneous abscess, furuncle and carbuncle	icd10	361194	1697	359497
L03	Diagnoses - main ICD10: L03 Cellulitis	icd10	361194	4247	356947
L12_ACTINKERA	Actinic keratosis	finngen	361194	1349	359845
L12_ATROPHICSKIN	Atrophic disorders of skin	finngen	361194	1757	359437
L12_NONIONRADISKIN	Skin changes due to chronic exposure to nonionizing radiation	finngen	361194	1501	359693
L12_OTHERDISSKINANDSUBCUTIS	Other disorders of skin and subcutaneous tissue, not elsewhere classified	finngen	361194	4147	357047
L12_SCARCONDITIONS	Scar conditions and fibrosis of skin	finngen	361194	1476	359718

L12_SKINSUBCUTISNAS	Other and unspecified disorders of skin and subcutaneous tissue	finngen	361194	3801	357393
L57	Diagnoses - main ICD10: L57 Skin changes due to chronic exposure to nonionising radiation	icd10	361194	1447	359747
L72	Diagnoses - main ICD10: L72 Follicular cysts of skin and subcutaneous tissue	icd10	361194	6644	354550
L82	Diagnoses - main ICD10: L82 Seborrhoeic keratosis	icd10	361194	2031	359163
L90	Diagnoses - main ICD10: L90 Atrophic disorders of skin	icd10	361194	1683	359511
L98	Diagnoses - main ICD10: L98 Other disorders of skin and subcutaneous tissue, not elsewhere classified	icd10	361194	4035	357159
LUNG_CANCER	Lung cancer and mesothelioma	finngen	361194	2007	359187
LUNG_CANCER_MESOT	Lung cancer and mesothelioma	finngen	361194	2007	359187
M06	Diagnoses - main ICD10: M06 Other rheumatoid arthritis	icd10	361194	1401	359793
M13	Diagnoses - main ICD10: M13 Other arthritis	icd10	361194	1110	360084
M13_ADHCAPSULITIS	Adhesive capsulitis of shoulder	finngen	361194	1198	359996
M13_ARTHROITISNAS	Other specific/unspecified arthritis	finngen	361194	1082	360112
M13_ARTHROSIS	#Arthrosis	finngen	361194	24977	336217
M13_ARTHROSIS_OTH	Other arthrosis	finngen	361194	5168	356026
M13_CERVICALGIA	Cervicalgia	finngen	361194	1049	360145
M13_DORSALGIA	Dorsalgia	finngen	361194	8799	352395
M13_DORSALGIANAS	Other/unspecified dorsalgia	finngen	361194	2118	359076
M13_DUPUTRYEN	Palmar fascial fibromatosis [Dupuytren]	finngen	361194	2948	358246
M13_ENTESOPATHYOTH	Other enthesopathies	finngen	361194	1024	360170
M13_FIBROBLASTIC	Fibroblastic disorders	finngen	361194	3190	358004
M13_GANGLION	Ganglion	finngen	361194	2239	358955
M13_HALLUXRIGIDUS	Hallux rigidus	finngen	361194	1130	360064
M13_HALLUXVALGUS	Hallux valgus (acquired)	finngen	361194	5370	355824
M13_IMPINGEMENT	Impingement syndrome of shoulder	finngen	361194	3420	357774
M13_JOINTOTH	Other specific joint derangements/joint disorders	finngen	361194	7943	353251
M13_LIMBPAIN	Pain in limb	finngen	361194	3674	357520
M13_LOWBACKPAIN	Low back pain	finngen	361194	5423	355771
M13_MENISCUSDERANGEMENTS	Meniscus derangement	finngen	361194	10831	350363

M13_OTHERJOINT	#Other joint disorders	finngen	361194	27347	333847
M13_POLYARTHROPATHIES	#Polyarthropathies	finngen	361194	3275	357919
M13_RHEUMA	Rheumatoid arthritis	finngen	361194	1605	359589
M13_ROTATORCUFF	Rotator cuff syndrome	finngen	361194	2285	358909
M13_SCIATICA	Siatica+with lumbago	finngen	361194	1153	360041
M13_SHOULDER	Shoulder lesions	finngen	361194	7243	353951
M13_SOFTOVERUSE	Soft tissue disorders related to use, overuse and pressure	finngen	361194	1132	360062
M13_SOFTTISSUENAS	Other specified/unspecified soft tissue disorders	finngen	361194	2930	358264
M13_SOFTTISSUEOTH	Other soft tissue disorders, not elsewhere classified	finngen	361194	7233	353961
M13_SPINSTENOSIS	Spinal stenosis	finngen	361194	1910	359284
M13_SPONDYLOPATHY	#Spondylopathies	finngen	361194	4393	356801
M13_SYNOTEND	Disorders of synovium and tendon	finngen	361194	5894	355300
M13_TRIGGERFINGER	Trigger finger	finngen	361194	1999	359195
M15	Diagnoses - main ICD10: M15 Polyarthrosis	icd10	361194	1264	359930
M16	Diagnoses - main ICD10: M16 Coxarthrosis [arthrosis of hip]	icd10	361194	9136	352058
M17	Diagnoses - main ICD10: M17 Gonarthrosis [arthrosis of knee]	icd10	361194	11497	349697
M19	Diagnoses - main ICD10: M19 Other arthrosis	icd10	361194	4165	357029
M20	Diagnoses - main ICD10: M20 Acquired deformities of fingers and toes	icd10	361194	7773	353421
M23	Diagnoses - main ICD10: M23 Internal derangement of knee	icd10	361194	11831	349363
M24	Diagnoses - main ICD10: M24 Other specific joint derangements	icd10	361194	1268	359926
M25	Diagnoses - main ICD10: M25 Other joint disorders, not elsewhere classified	icd10	361194	7218	353976
M47	Diagnoses - main ICD10: M47 Spondylosis	icd10	361194	2004	359190
M48	Diagnoses - main ICD10: M48 Other spondylopathies	icd10	361194	1890	359304
M51	Diagnoses - main ICD10: M51 Other intervertebral disk disorders	icd10	361194	4690	356504
M54	Diagnoses - main ICD10: M54 Dorsalgia	icd10	361194	8361	352833
M65	Diagnoses - main ICD10: M65 Synovitis and tenosynovitis	icd10	361194	2812	358382

M67	Diagnoses - main ICD10: M67 Other disorders of synovium and tendon	icd10	361194	2613	358581
M70	Diagnoses - main ICD10: M70 Soft tissue disorders related to use, overuse and pressure	icd10	361194	1079	360115
M72	Diagnoses - main ICD10: M72 Fibroblastic disorders	icd10	361194	3193	358001
M75	Diagnoses - main ICD10: M75 Shoulder lesions	icd10	361194	7040	354154
M79	Diagnoses - main ICD10: M79 Other soft tissue disorders, not elsewhere classified	icd10	361194	6946	354248
M84	Diagnoses - main ICD10: M84 Disorders of continuity of bone	icd10	361194	1065	360129
N13	Diagnoses - main ICD10: N13 Obstructive and reflux uropathy	icd10	361194	1359	359835
N20	Diagnoses - main ICD10: N20 Calculus of kidney and ureter	icd10	361194	3540	357654
N23	Diagnoses - main ICD10: N23 Unspecified renal colic	icd10	361194	1408	359786
N30	Diagnoses - main ICD10: N30 Cystitis	icd10	361194	1575	359619
N31	Diagnoses - main ICD10: N31 Neuromuscular dysfunction of bladder, not elsewhere classified	icd10	361194	1014	360180
N32	Diagnoses - main ICD10: N32 Other disorders of bladder	icd10	361194	4238	356956
N35	Diagnoses - main ICD10: N35 Urethral stricture	icd10	361194	2037	359157
N39	Diagnoses - main ICD10: N39 Other disorders of urinary system	icd10	361194	10551	350643
N40	Diagnoses - main ICD10: N40 Hyperplasia of prostate	icd10	361194	5109	356085
N47	Diagnoses - main ICD10: N47 Redundant prepuce, phimosis and paraphimosis	icd10	361194	1543	359651
N48	Diagnoses - main ICD10: N48 Other disorders of penis	icd10	361194	1317	359877
N50	Diagnoses - main ICD10: N50 Other disorders of male genital organs	icd10	361194	1829	359365
N60	Diagnoses - main ICD10: N60 Benign mammary dysplasia	icd10	361194	1157	360037
N63	Diagnoses - main ICD10: N63 Unspecified lump in breast	icd10	361194	1199	359995
N80	Diagnoses - main ICD10: N80 Endometriosis	icd10	361194	1496	359698

N81	Diagnoses - main ICD10: N81 Female genital prolapse	icd10	361194	7511	353683
N83	Diagnoses - main ICD10: N83 Noninflammatory disorders of ovary, Fallopian tube and broad ligament	icd10	361194	2215	358979
N84	Diagnoses - main ICD10: N84 Polyp of female genital tract	icd10	361194	6986	354208
N85	Diagnoses - main ICD10: N85 Other noninflammatory disorders of uterus, except cervix	icd10	361194	1489	359705
N87	Diagnoses - main ICD10: N87 Dysplasia of cervix uteri	icd10	361194	1102	360092
N90	Diagnoses - main ICD10: N90 Other noninflammatory disorders of vulva and perineum	icd10	361194	1077	360117
N92	Diagnoses - main ICD10: N92 Excessive, frequent and irregular menstruation	icd10	361194	8475	352719
N93	Diagnoses - main ICD10: N93 Other abnormal uterine and vaginal bleeding	icd10	361194	2455	358739
N94	Diagnoses - main ICD10: N94 Pain and other conditions associated with female genital organs and menstrual cycle	icd10	361194	1295	359899
N95	Diagnoses - main ICD10: N95 Menopausal and other perimenopausal disorders	icd10	361194	6496	354698
O02	Diagnoses - main ICD10: O02 Other abnormal products of conception	icd10	361194	1106	360088
O03	Diagnoses - main ICD10: O03 Spontaneous abortion	icd10	361194	1150	360044
O26	Diagnoses - main ICD10: O26 Maternal care for other conditions predominantly related to pregnancy	icd10	361194	1289	359905
O36	Diagnoses - main ICD10: O36 Maternal care for other known or suspected foetal problems	icd10	361194	1149	360045
O63	Diagnoses - main ICD10: O63 Long labour	icd10	361194	1060	360134
O68	Diagnoses - main ICD10: O68 Labour and delivery complicated by foetal stress [distress]	icd10	361194	1882	359312
O70	Diagnoses - main ICD10: O70 Perineal laceration during delivery	icd10	361194	3077	358117

O80	Diagnoses - main ICD10: O80 Single spontaneous delivery	icd10	361194	1672	359522
OTHER_ILD_CVD_COMORB	Other ILD-related CVD-co-morbidities	finngen	361194	2507	358687
PNEUMONIA	Pneumonias (Asthma/COPD co-morbidities)	finngen	361194	5900	355294
PULM_MEDICATIO_COMORB	Medication related adverse effects (Asthma/COPD)	finngen	361194	21706	339488
PULMONARYDG	Other pulmonary diagnosis	finngen	361194	25381	335813
R00	Diagnoses - main ICD10: R00 Abnormalities of heart beat	icd10	361194	2542	358652
R04	Diagnoses - main ICD10: R04 Haemorrhage from respiratory passages	icd10	361194	2836	358358
R06	Diagnoses - main ICD10: R06 Abnormalities of breathing	icd10	361194	4126	357068
R07	Diagnoses - main ICD10: R07 Pain in throat and chest	icd10	361194	24530	336664
R10	Diagnoses - main ICD10: R10 Abdominal and pelvic pain	icd10	361194	20240	340954
R11	Diagnoses - main ICD10: R11 Nausea and vomiting	icd10	361194	2271	358923
R13	Diagnoses - main ICD10: R13 Dysphagia	icd10	361194	3471	357723
R19	Diagnoses - main ICD10: R19 Other symptoms and signs involving the digestive system and abdomen	icd10	361194	8796	352398
R22	Diagnoses - main ICD10: R22 Localised swelling, mass and lump of skin and subcutaneous tissue	icd10	361194	1358	359836
R31	Diagnoses - main ICD10: R31 Unspecified haematuria	icd10	361194	11283	349911
R33	Diagnoses - main ICD10: R33 Retention of urine	icd10	361194	2364	358830
R35	Diagnoses - main ICD10: R35 Polyuria	icd10	361194	1773	359421
R39	Diagnoses - main ICD10: R39 Other symptoms and signs involving the urinary system	icd10	361194	2698	358496
R42	Diagnoses - main ICD10: R42 Dizziness and giddiness	icd10	361194	1680	359514
R50	Diagnoses - main ICD10: R50 Fever of unknown origin	icd10	361194	1156	360038
R51	Diagnoses - main ICD10: R51 Headache	icd10	361194	4271	356923

R55	Diagnoses - main ICD10: R55 Syncope and collapse	icd10	361194	5183	356011
R56	Diagnoses - main ICD10: R56 Convulsions, not elsewhere classified	icd10	361194	1077	360117
R59	Diagnoses - main ICD10: R59 Enlarged lymph nodes	icd10	361194	1011	360183
R63	Diagnoses - main ICD10: R63 Symptoms and signs concerning food and fluid intake	icd10	361194	1279	359915
R69	Diagnoses - main ICD10: R69 Unknown and unspecified causes of morbidity	icd10	361194	8280	352914
R79	Diagnoses - main ICD10: R79 Other abnormal findings of blood chemistry	icd10	361194	2622	358572
R87	Diagnoses - main ICD10: R87 Abnormal findings in specimens from female genital organs	icd10	361194	1084	360110
R91	Diagnoses - main ICD10: R91 Abnormal findings on diagnostic imaging of lung	icd10	361194	1130	360064
R93	Diagnoses - main ICD10: R93 Abnormal findings on diagnostic imaging of other body structures	icd10	361194	1217	359977
RHEU_ARTHRITIS_OTH	Other arthritis (FG)	finngen	361194	1212	359982
RHEUMA_NOS	Other/unspecified rheumatoid arthritis	finngen	361194	1281	359913
S01	Diagnoses - main ICD10: S01 Open wound of head	icd10	361194	1694	359500
S02	Diagnoses - main ICD10: S02 Fracture of skull and facial bones	icd10	361194	1351	359843
S09	Diagnoses - main ICD10: S09 Other and unspecified injuries of head	icd10	361194	1333	359861
S42	Diagnoses - main ICD10: S42 Fracture of shoulder and upper arm	icd10	361194	1791	359403
S52	Diagnoses - main ICD10: S52 Fracture of forearm	icd10	361194	5080	356114
S61	Diagnoses - main ICD10: S61 Open wound of wrist and hand	icd10	361194	1865	359329
S62	Diagnoses - main ICD10: S62 Fracture at wrist and hand level	icd10	361194	1763	359431
S72	Diagnoses - main ICD10: S72 Fracture of femur	icd10	361194	1803	359391
S82	Diagnoses - main ICD10: S82 Fracture of lower leg, including ankle	icd10	361194	4557	356637

SLEEP	Sleep disorders (combined)	finngen	361194	2951	358243
SNORING	Snoring	finngen	361194	1305	359889
STILL_ADULT	Adult-onset Still disease	finngen	361194	1486	359708
T39	Diagnoses - main ICD10: T39 Poisoning by nonopioid analgesics, antipyretics and antirheumatics	icd10	361194	1161	360033
T81	Diagnoses - main ICD10: T81 Complications of procedures, not elsewhere classified	icd10	361194	5550	355644
T82	Diagnoses - main ICD10: T82 Complications of cardiac and vascular prosthetic devices, implants and grafts	icd10	361194	1133	360061
T84	Diagnoses - main ICD10: T84 Complications of internal orthopaedic prosthetic devices, implants and grafts	icd10	361194	3719	357475
T85	Diagnoses - main ICD10: T85 Complications of other internal prosthetic devices, implants and grafts	icd10	361194	1501	359693
ULCERNAS	Ulcerative colitis, NAS	finngen	361194	1903	359291
V_MENTAL_BEHAV	Mental and behavioural disorders	finngen	361194	4302	356892
VI_NERVOUS	Diseases of the nervous system	finngen	361194	21323	339871
VII_EYE_ADNEXA	Diseases of the eye and adnexa	finngen	361194	29878	331316
VIII_EAR_MASTOID	Diseases of the ear and mastoid process	finngen	361194	5252	355942
X_RESPIRATORY	Diseases of the respiratory system	finngen	361194	25381	335813
XI_DIGESTIVE	Diseases of the digestive system	finngen	361194	115893	245301
XII_SKIN_SUBCUTAN	Diseases of the skin and subcutaneous tissue	finngen	361194	27074	334120
XIII_MUSCULOSKELET	Diseases of the musculoskeletal system and connective tissue	finngen	361194	77099	284095
XIV_GENITOURINARY	Diseases of the genitourinary system	finngen	361194	71620	289574
XIX_INJURY_POISON	Injury, poisoning and certain other consequences of external causes	finngen	361194	44796	316398
XV_PREGNANCY_BIRTH	Pregnancy, childbirth and the puerperium	finngen	361194	11959	349235
XVII_MALFORMAT_ABNORMAL	Congenital malformations, deformations and chromosomal abnormalities	finngen	361194	2121	359073
XVIII_MISCFINDINGS	Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	finngen	361194	97602	263592
XXI_HEALTHFACTORS	Factors influencing health status and contact with health services	finngen	361194	45947	315247

Z01	Diagnoses - main ICD10: Z01 Other special examinations and investigations of persons without complaint or reported diagnosis	icd10	361194	1370	359824
Z03	Diagnoses - main ICD10: Z03 Medical observation and evaluation for suspected diseases and conditions	icd10	361194	4951	356243
Z08	Diagnoses - main ICD10: Z08 Follow-up examination after treatment for malignant neoplasm	icd10	361194	4214	356980
Z09	Diagnoses - main ICD10: Z09 Follow-up examination after treatment for conditions other than malignant neoplasms	icd10	361194	8464	352730
Z12	Diagnoses - main ICD10: Z12 Special screening examination for neoplasms	icd10	361194	4152	357042
Z13	Diagnoses - main ICD10: Z13 Special screening examination for other diseases and disorders	icd10	361194	2236	358958
Z30	Diagnoses - main ICD10: Z30 Contraceptive management	icd10	361194	6392	354802
Z42	Diagnoses - main ICD10: Z42 Follow-up care involving plastic surgery	icd10	361194	1963	359231
Z43	Diagnoses - main ICD10: Z43 Attention to artificial openings	icd10	361194	1356	359838
Z45	Diagnoses - main ICD10: Z45 Adjustment and management of implanted device	icd10	361194	2209	358985
Z46	Diagnoses - main ICD10: Z46 Fitting and adjustment of other devices	icd10	361194	3614	357580
Z47	Diagnoses - main ICD10: Z47 Other orthopaedic follow-up care	icd10	361194	2774	358420
Z53	Diagnoses - main ICD10: Z53 Persons encountering health services for specific procedures, not carried out	icd10	361194	1754	359440

Table S2: Clinically-relevant phenotypes identified as significant in the *TTR* PheWAS. We report the Z scores observed in the overall analysis and in the sex-stratified analysis for both *TTR* and *RBP4*. Z scores surviving multiple testing correction are highlighted in bold. NA indicates associations not tested due the quality control applied. NS indicates phenotypes not significantly associated with *RBP4* variants.

Traits	<i>TTR</i> rsid	Z Score			<i>RBP4</i> rsid	Z score		
		Overall	Female	Male		Overall	Female	Male
I25 (Chronic ischemic heart disease)	rs140226130	2.41	4.75	0.06	NS			
I9_HEARTFAIL (Heart failure, strict)	rs73956431	4.27	0.65	4.69	rs1326222	5.02	4.37	3.18
I48 (Atrial fibrillation and flutter)	rs10163755	3.81	0.05	4.58	rs4917692	1.54	4.39	-1.15
R13 (Dysphagia)	rs2949506	3.18	4.61	-0.49	rs61886346	2.52	-0.35	4.31
K63 (Other diseases of intestine)	rs970866	-3.77	-0.68	-4.49	NS			
N31 (Neuromuscular dysfunction of bladder, not elsewhere classified)	rs9953311	-4.73	-3.58	-3.07	NS			
N39 (Other disorders of urinary system)	rs71173870	3.59	4.42	-0.14	NS			
N32 (Other disorders of bladder)	rs138038371	4.32	0.32	5.03	NS			
N20 (Calculus of kidney and ureter)	rs8090264	4.32	0.89	4.56	NS			
H26 (Other cataract)	rs12966815	3.02	4.40	-0.33	NS			
H33 (Retinal detachments and breaks)	rs117637258	3.3	4.39	0.63	NS			
M13 (SPINSTENOSIS (Spinal stenosis)	rs116937108	5.29	4.24	3.24	rs112288944	1.87	-1.61	4.34
KRA_PSY_ANXIETY (Anxiety disorders)	rs554521234	4.44	4.8	1.14	rs112059561	4.51	2.99	3.49
M13_FIBROBLASTIC (Fibroblastic disorders)	rs60487427	-3.6	0.49	-4.46	NS			
M13_SOFTTISSUES (Other specified/unspecified soft tissue disorders)	rs558461933	4.68	4.42	2.11	NS			
M75 (Shoulder lesions)	rs77728273	-3.34	-4.38	-0.19	NS			
K61 (Abscess of al and rectal regions)	rs72948149	4.77	2.72	3.91	NS			
K60 (Fissure and fistula of al and rectal regions)	rs72927361	-4.76	-3.39	-3.38	NS			
K11_BARRET (Barret esophagus)	rs147570462	5.30	2.56	4.64	rs12573026	5.33	1.72	5.33
K11_OESULC (Ulcer of esophagus)	rs74481699	4.51	1.82	4.29	NS			
C18 (Malign neoplasm of colon)	rs78431500	2.07	-2.14	4.68	rs142083973	3.7	0.33	4.65
C3_PRIMARY_LYMPHOID_HEMATOPOIETIC (Primary lymphoid and hematopoietic malign neoplasms)	rs17718949	4.51	3.63	2.81	NS			
T85 (Complications of other internal prosthetic devices, implants and grafts)	rs34444556	4.54	NA	4.20	NS			
T81 (Complications of procedures, not elsewhere classified)	rs182526571	2.4	-0.83	4.51	NS			
Z45 (Adjustment and management of implanted device)	rs117672477	4.51	2.93	3.43	NS			
O02 (Other abnormal products of conception)	rs139327590	4.40	4.38	NA	NS			

Table S3: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits related in the overall sample. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
FinnGen: K11_BARRET~Barret esophagus	rs147570462	0.00304	0.000575	1.19×10^{-7}	0.003
FinnGen: M13_SPINSTENOSIS~Spinal stenosis	rs116937108	0.00188	0.000355	1.21×10^{-7}	0.003
ICD10: K61~Abscess of anal and rectal regions	rs72948149	0.00198	0.000416	1.87×10^{-6}	0.033
ICD10: K60~Fissure and fistula of anal and rectal regions	rs72927361	-0.00332	0.000696	1.90×10^{-6}	0.033
ICD10: N31~Neuromuscular dysfunction of bladder, not elsewhere classified	rs9953311	-0.00123	0.000260	2.30×10^{-6}	0.039
FinnGen: M13_SOFTTISSUENAS~Other specified/unspecified soft tissue disorders	rs558461933	0.00503	0.00107	2.82×10^{-6}	0.045
ICD10: N31~Neuromuscular dysfunction of bladder, not elsewhere classified	rs575854233	-0.00127	0.000278	5.33×10^{-6}	0.067
ICD10: T85~Complications of other internal prosthetic devices, implants and grafts	rs34444556	0.00252	0.000555	5.50×10^{-6}	0.066
FinnGen: K11_OESULC~Ulcer of esophagus	rs74481699	0.00442	0.000981	6.43×10^{-6}	0.076
ICD10: Z45~Adjustment and management of implanted device	rs117672477	0.00210	0.000465	6.51×10^{-6}	0.077
FinnGen: C3_PRIMARY_LYMPHOID_HEMATOPOIETIC~Primary lymphoid and hematopoietic malignant neoplasms	rs17718949	0.00938	0.000208	6.57×10^{-6}	0.077
FinnGen: KRA_PSY_ANXIETY~Anxiety disorders	rs554521234	0.00279	0.000667	8.85×10^{-6}	0.096

Table S4: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits related in the female-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
ICD10: I25~Chronic ischaemic heart disease	rs140226130	0.00338	0.000711	2.00×10^{-6}	0.029
ICD10: R13~Dysphagia	rs2949506	0.00195	0.000422	3.95×10^{-6}	0.047
ICD10: N39~Other disorders of urinary system	rs71173870	0.00298	0.000675	9.81×10^{-6}	0.079
FinnGen: M13_SOFTTISSUENAS~Other specified/unspecified soft tissue disorders	rs558461933	0.00646	0.00146	9.92×10^{-6}	0.079
ICD10: H26~Other cataract	rs12966815	0.00253	0.000576	1.10×10^{-5}	0.079
ICD10: H33~Retinal detachments and breaks	rs117637258	0.00290	0.000660	1.12×10^{-5}	0.079
ICD10: O02~Other abnormal products of conception	rs139327590	0.00389	0.000888	1.16×10^{-5}	0.079
ICD10: M75~Shoulder lesions	rs77728273	-0.00379	0.000866	1.21×10^{-5}	0.079

Table S5: Variants localized on *TTR* target genomic region (NC_000018.9: 27,171,000 – 31,171,500) and their significantly associations with phenotypic traits related in the male-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
ICD10: N32~Other disorders of bladder	rs138038371	0.00893	0.00178	5.01×10^{-7}	0.010
FinnGen: I9_HEARTFAIL~Heart failure, strict	rs73956431	0.00529	0.00113	2.74×10^{-6}	0.042
ICD10: C18~Malignant neoplasm of colon	rs78431500	0.00579	0.00124	2.89×10^{-6}	0.044
FinnGen: K11_BARRET~Barret esophagus	rs147570462	0.00466	0.001	3.45×10^{-6}	0.051
ICD10: I48~Atrial fibrillation and flutter	rs10163755	0.00299	0.000653	4.63×10^{-6}	0.064
ICD10: N20~Calculus of kidney and ureter	rs8090264	0.00208	0.000455	5.23×10^{-6}	0.071
ICD10: T81~Complications of procedures, not elsewhere classified	rs182526571	0.00752	0.00167	6.57×10^{-6}	0.083
ICD10: K63~Other diseases of intestine	rs970866	-0.00507	0.00113	7.14×10^{-6}	0.086
FinnGen: M13_FIBROBLASTIC~Fibroblastic disorders	rs60487427	-0.00373	0.000838	8.38×10^{-6}	0.096

Table S6: *TTR* coding mutations in the UK Biobank sample investigated. Rsid, localization, imputation score, allelic frequency (AF), precursor and/or protein substitution, consequences of variants are reported.

RSID	variant	info_score	AF	Precursor_TTR	TTR	Consequences
rs138657343	18:29171879:G:A	0.823	0.0003	Arg5His	-	Missense_variant
rs1800458	18:29172865:G:A	1	0.0814	Gly26Ser	Gly26Ser	Missense_variant
rs121918074	18:29175210:C:A	0.863	0.00005	His110Asn	His90Asn	Missense_variant
rs28933981	18:29178610:C:T	0.925	0.0037	Thr139Met	Thr119Met	Missense_variant
rs2276382	18:29178611:G:A	0.823	0.00005	Thr139=	Thr119=	Synonymous_variant
rs76992529	18:29178618:G:A	1	0.00008	Val142Ile	Val122Ile	Missense_variant

Table S7: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the overall-sample analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
FinnGen: K11_BARRET~Barret esophagus	rs12573026	0.00124	0.000232	9.96×10^{-8}	0.002
FinnGen: I9_HEARTFAIL~Heart failure, strict	rs1326222	0.000935	0.000186	5.25×10^{-7}	0.006
FinnGen: KRA_PSY_ANXIETY~Anxiety disorders	rs112059561	0.00228	0.000506	6.44×10^{-6}	0.042

Table S8: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the female-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
ICD10: I48~Atrial fibrillation and flutter	rs4917692	0.00152	0.000346	1.15×10^{-5}	0.076
FinnGen: I9_HEARTFAIL~Heart failure, strict	rs1326222	0.000802	0.000183	1.23×10^{-5}	0.076

Table S8: Variants localized on *RBP4* target genomic region (NC_000010.10: 93,353,000 – 97,353,500) and their significantly associations with phenotypic traits in the male-specific analysis. Phenotypic traits are reported with respectively ICD-10 and FinnGen codes. Information about beta value, SE, p-value and FDR q-value are also reported. Information about allele frequency and minor allele frequency are reported in Table S10.

Phenotypic Trait	RSID	beta	SE	p-value	FDR
FinnGen: K11_BARRET~Barret esophagus	rs12573026	0.00217	0.000407	1.01×10^{-7}	0.001
ICD10: C18~Malignant neoplasm of colon	rs142083973	0.00543	0.00117	3.40×10^{-6}	0.018
FinnGen: M13_SPINSTENOSIS~Spinal stenosis	rs112288944	0.00466	0.00107	1.42×10^{-5}	0.064
ICD10: R13~Dysphagia	rs61886346	0.00284	0.000659	1.66×10^{-5}	0.073

Table S10: Allele frequencies of *TTR* and *RBP4* significant variants identified. Ref = reference allele on the forward strand; alt = alternate allele (not necessarily minor allele); AF = allele frequency; MAF = minor allele frequency in the n_complete_samples defined for associated phenotype.

PHENOTYPIC TRAIT		RSID <i>TTR</i>	REF	ALT	AF	MA	MAF	BETA	SE	P-VAL	FDR
BOTH SEXES	FinnGen: K11_BARRET~Barret esophagus	rs147570462	A	G	0.0233	G	0.0240	0.00304	0.000575	1.19×10^{-7}	0.003
	FinnGen: M13_SPINSTENOSIS~Spinal stenosis	rs116937108	T	C	0.0625	C	0.0626	0.00188	0.000355	1.21×10^{-7}	0.003
	ICD10: K61~Abscess of anal and rectal regions	rs72948149	C	T	0.0248	T	0.0248	0.00198	0.000416	1.87×10^{-6}	0.033
	ICD10: K60~Fissure and fistula of anal and rectal regions	rs72927361	C	T	0.0183	T	0.0184	-0.00332	0.000696	1.90×10^{-6}	0.033
	ICD10: N31~Neuromuscular dysfunction of bladder, not elsewhere classified	rs9953311	T	G	0.9349	T	0.0650	-0.00123	0.000260	2.30×10^{-6}	0.039
	FinnGen: M13_SOFTTISSUENAS~Other specified/unspecified soft tissue disorders	rs558461933	C	A	0.0116	A	0.0114	0.00503	0.00107	2.82×10^{-6}	0.045
	ICD10: N31~Neuromuscular dysfunction of bladder, not elsewhere classified	rs575854233	CA	C	0.9372	CA	0.0594	-0.00127	0.000278	5.33×10^{-6}	0.067

FEMALES	ICD10: T85~Complications of other internal prosthetic devices, implants and grafts	rs34444556	A	G	0.0237	G	0.0229	0.00252	0.000555	5.50×10^{-6}	0.066
	FinnGen: K11_OESULC~Ulcer of esophagus	rs74481699	C	G	0.0125	G	0.0125	0.00442	0.000981	6.43×10^{-6}	0.076
	ICD10: Z45~Adjustment and management of implanted device	rs117672477	A	G	0.0450	G	0.0448	0.00210	0.000465	6.51×10^{-6}	0.077
	FinnGen: C3_PRIMARY_LYMPHOID_HEMATOPOIETIC~Primary lymphoid and hematopoietic malignant neoplasms	rs17718949	G	C	0.3899	C	0.3899	0.00938	0.000208	6.57×10^{-6}	0.077
	FinnGen: KRA_PSY_ANXIETY~Anxiety disorders	rs554521234	C	T	0.0116	T	0.0125	0.00279	0.000667	8.85×10^{-6}	0.096
	ICD10: I25~Chronic ischaemic heart disease	rs140226130	T	TTCTTTTTC	0.0917	TTCTTTTTC	0.0908	0.00338	0.000711	2.00×10^{-6}	0.029
	ICD10: R13~Dysphagia	rs2949506	C	T	0.1977	T	0.1974	0.00195	0.000422	3.95×10^{-6}	0.047
	ICD10: N39~Other disorders of urinary system	rs71173870	C	CA	0.6474	C	0.3662	0.00298	0.000675	9.81×10^{-6}	0.079
	FinnGen: M13_SOFTTISSUENAS~Other specified/unspecified soft tissue disorders	rs558461933	C	A	0.0116	A	0.0115	0.00646	0.00146	9.92×10^{-6}	0.079
	ICD10:H26~Other cataract	rs12966815	A	G	0.4942	G	0.4941	0.00253	0.000576	1.10×10^{-5}	0.079
	ICD10: H33~Retinal detachments and breaks	rs117637258	C	T	0.0352	T	0.0353	0.00290	0.000660	1.12×10^{-5}	0.079
	ICD10: O02~Other abnormal products of conception	rs139327590	A	G	0.0209	G	0.0204	0.00389	0.000888	1.16×10^{-5}	0.079

	ICD10: M75~Shoulder lesions	rs77728273	C	T	0.0743	T	0.0736	-0.00379	0.000866	1.21×10 ⁻⁵	0.079
MALES	ICD10: N32~Other disorders of bladder	rs138038371	T	A	0.0175	A	0.0176	0.00893	0.00178	5.01×10 ⁻⁷	0.010
	FinnGen: I9_HEARTFAIL~Heart failure, strict	rs73956431	C	T	0.0148	T	0.0147	0.00529	0.00113	2.74×10 ⁻⁶	0.042
	ICD10: C18~Malignant neoplasm of colon	rs78431500	G	C	0.0182	C	0.0179	0.00579	0.00124	2.89×10 ⁻⁶	0.044
	FinnGen: K11_BARRET~Barret esophagus	rs147570462	A	G	0.0233	G	0.0243	0.00466	0.001	3.45×10 ⁻⁶	0.051
	ICD10: I48~Atrial fibrillation and flutter	rs10163755	G	A	0.7508	G	0.2495	0.00299	0.000653	4.63×10 ⁻⁶	0.064
	ICD10: N20~Calculus of kidney and ureter	rs8090264	A	T	0.6314	A	0.3750	0.00208	0.000455	5.23×10 ⁻⁶	0.071
	ICD10: T81~Complications of procedures, not elsewhere classified	rs182526571	C	T	0.0168	T	0.0169	0.00752	0.00167	6.57×10 ⁻⁶	0.083
	ICD10: K63~Other diseases of intestine	rs970866	C	T	0.9317	C	0.0682	-0.00507	0.00113	7.14×10 ⁻⁶	0.086
	FinnGen: M13_FIBROBLASTIC~Fibroblastic disorders	rs60487427	C	T	0.0659	T	0.0661	-0.00373	0.000838	8.38×10 ⁻⁶	0.096
PHENOTYPIC TRAIT		RSID <i>RBP4</i>	REF	ALT	AF	MA	MAF	BETA	SE	P-VAL	FDR
H SEX	FinnGen: K11_BARRET~Barret esophagus	rs12573026	T	C	0.1487	C	0.1487	0.00124	0.000232	9.96×10 ⁻⁸	0.002

	FinnGen: I9_HEARTFAIL~Heart failure, strict	rs1326222	C	T	0.1913	T	0.1915	0.000935	0.000186	5.25×10^{-7}	0.006
	FinnGen: KRA_PSY_ANXIETY~Anxiety disorders	rs112059561	G	T	0.0175	T	0.0174	0.00228	0.000506	6.44×10^{-6}	0.042
FEMALES	ICD10: I48~Atrial fibrillation and flutter	rs4917692	A	G	0.3702	G	0.3708	0.00152	0.000346	1.15×10^{-5}	0.076
	FinnGen: I9_HEARTFAIL~Heart failure, strict	rs1326222	C	T	0.1913	T	0.1932	0.000802	0.000183	1.23×10^{-5}	0.076
MALES	FinnGen: K11_BARRET~Barret esophagus	rs12573026	T	C	0.1487	C	0.1494	0.00217	0.000407	1.01×10^{-7}	0.001
	ICD10: C18~Malignant neoplasm of colon	rs142083973	C	A	0.0196	A	0.0196	0.00543	0.00117	3.40×10^{-6}	0.018
	FinnGen: M13_SPINSTENOSIS~Spinal stenosis	rs112288944	G	A	0.0156	A	0.0160	0.00466	0.00107	1.42×10^{-5}	0.064
	ICD10: R13~Dysphagia	rs61886346	C	T	0.0661	T	0.0663	0.00284	0.000659	1.66×10^{-5}	0.073